CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
11.28
2.17%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Viatris Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 11.53
Open* 11.48
1-Year Change* 16.31%
Day's Range* 11.17 - 11.48
52 wk Range 8.74-12.49
Average Volume (10 days) 12.65M
Average Volume (3 months) 191.22M
Market Cap 13.52B
P/E Ratio 7.47
Shares Outstanding 1.20B
Revenue 15.47B
EPS 1.51
Dividend (Yield %) 4.25909
Beta 1.12
Next Earnings Date Feb 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 12, 2024 11.28 -0.24 -2.08% 11.52 11.53 11.16
Apr 11, 2024 11.53 -0.12 -1.03% 11.65 11.68 11.49
Apr 10, 2024 11.67 0.07 0.60% 11.60 11.72 11.59
Apr 9, 2024 11.78 0.09 0.77% 11.69 11.80 11.66
Apr 8, 2024 11.71 -0.01 -0.09% 11.72 11.86 11.65
Apr 5, 2024 11.76 0.12 1.03% 11.64 11.79 11.60
Apr 4, 2024 11.71 -0.34 -2.82% 12.05 12.10 11.69
Apr 3, 2024 11.99 0.13 1.10% 11.86 12.19 11.86
Apr 2, 2024 11.91 0.09 0.76% 11.82 11.96 11.77
Apr 1, 2024 11.89 -0.03 -0.25% 11.92 11.92 11.75
Mar 28, 2024 11.90 0.05 0.42% 11.85 11.98 11.74
Mar 27, 2024 11.79 0.13 1.11% 11.66 11.82 11.60
Mar 26, 2024 11.56 -0.26 -2.20% 11.82 11.91 11.55
Mar 25, 2024 11.79 -0.06 -0.51% 11.85 11.96 11.78
Mar 22, 2024 11.79 -0.23 -1.91% 12.02 12.10 11.79
Mar 21, 2024 11.97 0.08 0.67% 11.89 12.02 11.85
Mar 20, 2024 11.84 0.09 0.77% 11.75 11.88 11.68
Mar 19, 2024 11.83 0.14 1.20% 11.69 11.87 11.67
Mar 18, 2024 11.72 -0.04 -0.34% 11.76 11.90 11.68
Mar 15, 2024 11.90 0.16 1.36% 11.74 11.95 11.74

Viatris Inc. Events

Time (UTC) Country Event
Monday, May 6, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Viatris Inc Earnings Release
Q1 2024 Viatris Inc Earnings Release

Forecast

-

Previous

-
Monday, August 5, 2024

Time (UTC)

12:30

Country

US

Event

Q2 2024 Viatris Inc Earnings Release
Q2 2024 Viatris Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 16262.7 17886.3 11946 11500.5 11433.9
Revenue 16262.7 17886.3 11946 11500.5 11433.9
Cost of Revenue, Total 9230.2 11326.4 7404.2 6948.6 6861.9
Gross Profit 7032.5 6559.9 4541.8 4551.9 4572
Total Operating Expense 14651.6 17928.3 12173.6 10795.7 10553.7
Selling/General/Admin. Expenses, Total 3605.9 3893.6 2571.4 2416.9 2274.3
Research & Development 659.8 654.6 507.5 518.8 568.7
Unusual Expense (Income) 1155.7 2053.7 1690.5 911.4 848.8
Operating Income 1611.1 -42 -227.6 704.8 880.2
Interest Income (Expense), Net Non-Operating -592.4 -700.2 -548.4 -587.3 -566.2
Other, Net 1794.5 77.8 54.8 36.9 -15.6
Net Income Before Taxes 2813.2 -664.4 -721.2 154.4 298.4
Net Income After Taxes 2078.6 -1269.1 -669.9 16.8 338
Minority Interest
Net Income Before Extra. Items 2078.6 -1269.1 -669.9 16.8 338
Net Income 2078.6 -1269.1 -669.9 16.8 352.5
Income Available to Common Excl. Extra. Items 2078.6 -1269.1 -669.9 16.8 338
Income Available to Common Incl. Extra. Items 2078.6 -1269.1 -669.9 16.8 352.5
Diluted Net Income 2078.6 -1269.1 -669.9 16.8 352.5
Diluted Weighted Average Shares 1217.4 1208.8 601.2 516.5 516.5
Diluted EPS Excluding Extraordinary Items 1.70741 -1.04988 -1.11427 0.03253 0.6544
Diluted Normalized EPS 2.41664 0.05444 0.71345 1.1795 1.72259
Total Extraordinary Items 14.5
Dividends per Share - Common Stock Primary Issue 0.48 0.33
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 3918.6 3729.1 3876 4078.2 4116.8
Revenue 3918.6 3729.1 3876 4078.2 4116.8
Cost of Revenue, Total 2197.1 2100.2 2285.9 2236 2350.5
Gross Profit 1721.5 1628.9 1590.1 1842.2 1766.3
Total Operating Expense 3615.2 3351.1 4072.9 3524.4 3568.5
Selling/General/Admin. Expenses, Total 954 884.7 1056.4 891.8 838.2
Research & Development 207.9 180.9 180.9 174.9 162
Unusual Expense (Income) 256.2 185.3 549.7 221.7 217.8
Operating Income 303.4 378 -196.9 553.8 548.3
Interest Income (Expense), Net Non-Operating -143.7 -147 -147.1 -153.2 -145.8
Other, Net 173.3 91.7 1812.9 26.9 -13.2
Net Income Before Taxes 333 322.7 1468.9 427.5 389.3
Net Income After Taxes 264 224.7 1011.2 354.3 313.9
Net Income Before Extra. Items 264 224.7 1011.2 354.3 313.9
Net Income 264 224.7 1011.2 354.3 313.9
Income Available to Common Excl. Extra. Items 264 224.7 1011.2 354.3 313.9
Income Available to Common Incl. Extra. Items 264 224.7 1011.2 354.3 313.9
Diluted Net Income 264 224.7 1011.2 354.3 313.9
Diluted Weighted Average Shares 1203.5 1205.6 1221.3 1218.1 1217.1
Diluted EPS Excluding Extraordinary Items 0.21936 0.18638 0.82797 0.29086 0.25791
Dividends per Share - Common Stock Primary Issue 0.12 0.12 0.12 0.12 0.12
Diluted Normalized EPS 0.38989 0.2934 1.1471 0.4417 0.4022
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 10635.4 10902.9 12867.5 6757.3 6367.7
Cash and Short Term Investments 1337.8 790.4 929.3 541.4 445.6
Cash & Equivalents 1259.9 701.2 844.4 475.6 388.1
Short Term Investments 77.9 89.2 84.9 65.8 57.5
Total Receivables, Net 3814.5 4266.4 4843.8 3058.8 2881
Accounts Receivable - Trade, Net 3243.8 3774.4 3891.3 2640.1 2416.5
Total Inventory 3519.5 3977.7 5471.9 2670.9 2580.2
Prepaid Expenses 194.6 256.7 267.8 156.7 130.6
Other Current Assets, Total 1769 1611.7 1354.7 329.5 330.3
Total Assets 50022.2 54842.8 61553 31255.5 32734.9
Property/Plant/Equipment, Total - Net 3283.8 3479.4 3783.5 2404.2 2170.2
Property/Plant/Equipment, Total - Gross 5343.1 5879.9 6045.5 4377.5 3974.5
Accumulated Depreciation, Total -2059.3 -2400.5 -2262 -1973.3 -1804.3
Goodwill, Net 10425.8 12113.7 12347 9590.6 9747.8
Intangibles, Net 22607.1 26134.2 29683.2 11649.9 13664.6
Long Term Investments 94 0 47.9 92.2 138.7
Other Long Term Assets, Total 2976.1 2212.6 2823.9 761.3 645.9
Total Current Liabilities 6746.2 9884.4 10562.9 5569.1 4587.8
Accounts Payable 1158 1056.1 1345.7 1528.1 1617
Accrued Expenses 2188.9 3226.4 2735.9 1563.6 1279.2
Notes Payable/Short Term Debt 0 1493 1100.9 0 1.9
Current Port. of LT Debt/Capital Leases 1250.5 1860.3 2256.3 1457.6 655.2
Other Current Liabilities, Total 2148.8 2248.6 3124.1 1019.8 1034.5
Total Liabilities 28949.9 34350.1 38598.9 19371.7 20567.8
Total Long Term Debt 18015.2 19717.1 22429.2 11214.3 13161.2
Long Term Debt 18015.2 19717.1 22429.2 11214.3 13161.2
Deferred Income Tax 2432 2815 3123.7 1627.5 1722
Minority Interest
Other Liabilities, Total 1756.5 1933.6 2483.1 960.8 1096.8
Total Equity 21072.3 20492.7 22954.1 11883.8 12167.1
Common Stock 12.1 12.1 12.1 6.1 6
Additional Paid-In Capital 18645.8 18536.1 18438.8 8643.5 8591.4
Retained Earnings (Accumulated Deficit) 5175.6 3688.8 5361.2 6031.1 6010.7
Treasury Stock - Common 0 -999.7 -999.7
Unrealized Gain (Loss) -2.3 0 1.2 0.6 0
Other Equity, Total -2758.9 -1744.3 -859.2 -1797.8 -1441.3
Total Liabilities & Shareholders’ Equity 50022.2 54842.8 61553 31255.5 32734.9
Total Common Shares Outstanding 1213.79 1209.51 1206.9 516.149 515.799
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 10932 9778 9630.3 10635.4 10487.8
Cash and Short Term Investments 1389.8 711.4 587.6 1337.8 721
Cash & Equivalents 1309.6 629.2 506.6 1259.9 646.7
Short Term Investments 80.2 82.2 81 77.9 74.3
Total Receivables, Net 3738.5 3607.3 3497.5 3814.5 3333.9
Accounts Receivable - Trade, Net 3231 3123.7 3021.9 3243.8 2829.8
Total Inventory 3671.9 3641.5 3664.3 3519.5 3380.4
Prepaid Expenses 334.4 370.6 239.7 194.6 237.1
Other Current Assets, Total 1797.4 1447.2 1641.2 1769 2815.4
Total Assets 48742.6 48695.2 49290.2 50022.2 48662.6
Property/Plant/Equipment, Total - Net 3174.3 3233.6 3261.6 3283.8 3303.2
Property/Plant/Equipment, Total - Gross 5284.8 5296.6 5398.9 5343.1 5282.8
Accumulated Depreciation, Total -2110.5 -2063 -2137.3 -2059.3 -1979.6
Goodwill, Net 10278.1 10532.5 10573.2 10425.8 10054.6
Intangibles, Net 21280.5 22084.4 22701.6 22607.1 23013.3
Long Term Investments 165.7 154.2 94
Other Long Term Assets, Total 2912 2912.5 3123.5 2976.1 1803.7
Total Current Liabilities 6834 6523.8 6108.1 6746.2 6521.4
Accounts Payable 1218.5 1309.6 1415.4 1158 791.2
Accrued Expenses 2231.3 2001 2130.1 2188.9 2271
Notes Payable/Short Term Debt 0.1 23.2 204.6 0 500.4
Current Port. of LT Debt/Capital Leases 1298.7 1325.6 500.1 1250.5 755
Other Current Liabilities, Total 2085.4 1864.4 1857.9 2148.8 2203.8
Total Liabilities 27877 27851.9 28362.3 28949.9 29480.3
Total Long Term Debt 17076.9 17246 18069.4 18015.2 18724.5
Long Term Debt 17076.9 17246 18069.4 18015.2 18724.5
Deferred Income Tax 2319 2407.8 2465 2432 2489.3
Other Liabilities, Total 1647.1 1674.3 1719.8 1756.5 1745.1
Total Equity 20865.6 20843.3 20927.9 21072.3 19182.3
Common Stock 12.2 12.2 12.2 12.1 12.1
Additional Paid-In Capital 18760.7 18719.4 18679.6 18645.8 18616.8
Retained Earnings (Accumulated Deficit) 5553 5369.1 5252.5 5175.6 4312.5
Unrealized Gain (Loss) -2.5 -1.3 -1.6 -2.3 -2.7
Other Equity, Total -3206 -3004.3 -2763 -2758.9 -3756.4
Total Liabilities & Shareholders’ Equity 48742.6 48695.2 49290.2 50022.2 48662.6
Total Common Shares Outstanding 1199.66 1199.15 1198.98 1213.79 1212.65
Treasury Stock - Common -251.8 -251.8 -251.8
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 2078.6 -1269.1 -669.9 16.8 352.5
Cash From Operating Activities 2952.6 3016.9 1231.8 1803.7 2341.7
Cash From Operating Activities 3027.6 4506.5 2216.1 2019.3 2109.9
Deferred Taxes -25.9 675.7 -213.2 -192.6 -264.3
Non-Cash Items -1205.1 908.6 595.1 468 332.6
Cash Taxes Paid 735.2 641.7 324.4 278.6 228.6
Cash Interest Paid 642.5 684.8 555.4 470.6 460.8
Changes in Working Capital -922.6 -1804.8 -696.3 -507.8 -189
Cash From Investing Activities 1520.5 -117.8 -301.1 -525.4 -1210.4
Capital Expenditures -443 -509.4 -681.2 -406 -1195.6
Other Investing Cash Flow Items, Total 1963.5 391.6 380.1 -119.4 -14.8
Cash From Financing Activities -3877.9 -3012 -605.7 -1169 -1090.9
Financing Cash Flow Items -19.5 -513.9 -205 -74.2 -45
Issuance (Retirement) of Stock, Net 3.3 0 0.6 8.1 -414.2
Issuance (Retirement) of Debt, Net -3280.1 -2099.1 -401.3 -1102.9 -631.7
Foreign Exchange Effects -38.9 -30.9 33.8 -7.5 -21
Net Change in Cash 556.3 -143.8 358.8 101.8 19.4
Total Cash Dividends Paid -581.6 -399
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 224.7 2078.6 1067.4 713.1 399.2
Cash From Operating Activities 971.2 2952.6 2810 1941 1138.5
Cash From Operating Activities 730 3027.6 2157.8 1458.3 736
Deferred Taxes -26.7 -25.9 -179.5 -157.6 -52.8
Non-Cash Items 74.6 -1205.1 285.7 71.5 71.2
Changes in Working Capital -31.4 -922.6 -521.4 -144.3 -15.1
Cash From Investing Activities -749.5 1520.5 -264 -149 -66.9
Capital Expenditures -82.5 -443 -277.1 -161.4 -71.9
Other Investing Cash Flow Items, Total -667 1963.5 13.1 12.4 5
Cash From Financing Activities -974.7 -3877.9 -2547.3 -1788.6 -1009
Financing Cash Flow Items -36.3 -19.5 -34.5 -33.6 -26
Issuance (Retirement) of Stock, Net -249.1 3.3 2.5 0.7
Issuance (Retirement) of Debt, Net -545.5 -3280.1 -2079.2 -1465.1 -837.9
Foreign Exchange Effects 1.2 -38.9 -54.5 -40.2 -11.4
Net Change in Cash -751.8 556.3 -55.8 -36.8 51.2
Total Cash Dividends Paid -143.8 -581.6 -436.1 -290.6 -145.1

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Viatris Inc. Company profile

Viatris (VTRS) is a global healthcare company. It was formed in 2020 through the merger of Pfizer’s (PFE) off-patent branded and generic medicines division Upjohn and pharmaceutical firm Mylan. 

The merger of Mylan and Upjohn was announced in July 2019 and received final regulatory clearance in October 2020. Pfizer shareholders own 57% of Viatris and Mylan shareholders own 43%, according to the merger announcement. Viatris started trading on the Nasdaq Stock Exchange under the ticker VTRS in November 2020. 

Viatris is headquartered in Canonsburg, Pittsburgh, US. The company is operational in over 165 countries and has global centres in Shanghai, China and Hyderabad, India. 

Viatris operates about 40 manufacturing sites which produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients. The firm also produces numerous complex generics, biosimilars and global key brands.

Viatris offers treatment options across more than 10 major therapeutic areas covering a wide variety of non-communicable and infectious diseases. According to the company’s website, 50% of its total active pharmaceutical ingredient (API) capacity is devoted to antiretroviral (ARV), which is used against HIV infection. 

Some of the well-known and key brands under Viatris are anxiety treatment drug Xanax, antidepressant Zoloft, anti-inflammatory drug Celebrex and erectile dysfunction therapy Viagra, among others. Viatris also offers global biosimilars franchises focused on the areas of oncology, immunology, endocrinology, ophthalmology and dermatology.

Industry: Pharmaceuticals (NEC)

1000 Mylan Boulevard
CANONSBURG
PENNSYLVANIA 15317
US

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

ETH/USD

3,265.70 Price
+6.270% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Gold

2,351.11 Price
+0.330% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0109%
Overnight fee time 21:00 (UTC)
Spread 0.30

BTC/USD

66,374.40 Price
+3.840% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

18,094.90 Price
+0.570% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading